Nantes, France, March 14, 2011 – The European Personalised Medicine Diagnostics association (EPEMED) today announced the publication of a new white paper in the March, 2011 issue of Future Medicine’s Journal of Personalized Medicine.
The paper explores specific challenges and market entry barriers in Europe faced by personalized medicine companies and their products, with a focus on reimbursement issues for high value diagnostic tests. The paper concludes that, while appropriate diagnostic reimbursement is a global issue, Europe presents particular inter- and intra-national heterogeneity, decentralized processes and a lack of transparency when compared to therapeutic reimbursement. As a consequence, few advanced diagnostic tests reach the broad European patient population and European innovation is impeded. A copy of this paper is available online at the Future Medicine web site (http://www.futuremedicine.com/toc/pme/8/2).
“This paper articulates some of the country-specific and European-wide challenges to personalized medicine while exploring potential solutions.” said Iain Miller PhD, co-author and founding member of EPEMED, and Executive Director Theranostics Strategy and Business Development at bioMerieux. “We hope that the EPEMED community, by highlighting such issues and serving as a forum for best practice sharing, can help drive solutions and bring medical diagnostic innovation to more patients” said Alain Huriez MD, Chairman and founder of EPEMED and CEO of TcLand Expression.
The new white paper is the latest in a series of EPEMED’s 2010 initiatives. In September 2010, EPEMED held its first webinar on Personalized Medicine in Europe, while in October 2010 the first EPEMED annual conference was held at the French Senate, with a focus on the public health and financial consequences of Personalized Medicine. Similar initiatives being planned for 2011 include a webinar in May and the 2nd annual conference in November.
About EPEMED
EPEMED, the European Personalized Medicine Diagnostics Association, www.epemed.org, is a dynamic non profit association formed in 2009. EPEMED’s focus is to improve patient outcomes while reducing costs through the use of information derived from individual diagnostics to better target therapy. EPEMED will do so by providing a platform for harmonization of the development and implementation of value-based diagnostics across Europe, to make personalized medicine a reality.
Specifically, EPEMED provides:
- Education, awareness and promotion of the benefits of personalized medicine
- A forum to share best practices
- Input to policy makers on relevant legislation
EPEMED counts diverse membership from the diagnostic, pharmaceutical, professional service and academic communities.
EPEMED
Information available on www.epemed.org (regular updates).
Membership conditions available at www.epemed.org & membership@epemed.org
Further information by writing at contact@epemed.org
Press contacts
ALIZE RP Caroline Carmagnol +33 (0)6 64 18 99 59 / caroline@alizerp.com
Anne-Sophie Cosquéric + 33 (0) 1 42 68 86 41 / anne-sophie@alizerp.com EPEMED - contact@epemed.org
